Abstract:Amidst a global rise in lung cancer occurrences, conventional therapies continue to pose substantial side effects and possess notable toxicities while lacking specificity. Counteracting this, the incorporation of nanomedicines can notably enhance drug delivery at tumor sites, extend a drug's half-life and mitigate inadvertent toxic and adverse impacts on healthy tissues, substantially influencing lung cancer's early detection and targeted therapy. Numerous studies signal that while the nano-characteristics of lung cancer nanomedicines play a pivotal role, further interplay with immune, photothermal, and genetic factors exist. This review posits that the progression towards multimodal combination therapies could potentially establish an efficacious platform for multimodal targeted lung cancer treatments. Current nanomedicines split into active and passive targeting. Active therapies focus on a single target, often with unsatisfactory results. Yet, developing combination systems targeting multiple sites could chart new paths in lung cancer therapy. Conversely, low drug delivery rates limit passive therapies. Utilizing the EPR effect to bind specific ligands on nanoparticles to tumor cell receptors might create a new regime combining active-passive targeting, potentially elevating the nanomedicines' concentration at target sites. This review collates recent advancements through the lens of nanomedicine's attributes for lung cancer therapeutics, the novel carrier classifications, targeted therapeutic modalities and their mechanisms, proposing that the emergence of multi-target nanocomposite therapeutics, combined active-passive targeting therapies and multimodal combined treatments will pioneer novel approaches and tools for future lung cancer clinical therapies.

Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer

Application of nano-radiosensitizers in non-small cell lung cancer

Advances of Nanomedicine in Radiotherapy

Recent Progresses on Radiotherapeutics-Based Treatment of Cancer with Two-Dimensional Nanomaterials

Emerging Nanoradiosensitizers and Nanoradioprotectants for Enhanced Cancer Theranostics

Empowering Radiotherapy: Harnessing Nanomedicines to Enhance Radiation Response and Boost Antitumor Efficacy

Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Nano-immunotherapy for Lung Cancer

Multifunctional High-Z Nanoradiosensitizers for Multimodal Synergistic Cancer Therapy.

Targeted Delivery of Nano-Radiosensitizers for Tumor Radiotherapy

Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization

Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection

Nanomedicine Embraces Cancer Radio-Immunotherapy: Mechanism, Design, Recent Advances, and Clinical Translation.

Multifunctional high-<i>Z</i> nanoradiosensitizers for multimodal synergistic cancer therapy

Nanotechnology and Nanomedicine: A Promising Avenue for Lung Cancer Diagnosis and Therapy

Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer